Clinical Trials Logo

Antithrombin III Deficiency clinical trials

View clinical trials related to Antithrombin III Deficiency.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT06096116 Not yet recruiting - Clinical trials for Acquired Antithrombin Deficiency

Phase 3 Study on the Efficacy and Safety of Human Plasma Derived Antithrombin (Atenativ) in Heparin-resistant Patients Scheduled to Undergo Cardiac Surgery Necessitating Cardiopulmonary Bypass

Start date: June 2024
Phase: Phase 3
Study type: Interventional

The primary objective of this study is to evaluate the efficacy of two different doses of Atenativ, versus placebo, in restoring heparin responsiveness in adult patients undergoing cardiopulmonary bypass (CPB) for cardiac surgery.

NCT ID: NCT05891899 Not yet recruiting - Clinical trials for Antithrombin III Deficiency

Belgian Antithrombin Deficiency Registry

Start date: May 2024
Phase:
Study type: Observational [Patient Registry]

Inherited antithrombin deficiency is a rare autosomal dominant disorder that predisposes to the development of venous thromboembolism, even at young age. Inherited AT deficiency is considered the most severe form of inherited thrombophilia, increasing up to 40 times the risk of venous thrombosis. Our center has been performing research on antithrombin deficiency for several years. Therefore, it was decided to initiate a registry for patients with inherited antithrombin deficiency with the goal to gain more insight into what drives the development of a thrombotic event in patients with AT deficiency, both at the environmental level (lifestyle, management of risk situations, presence of additional thrombotic risk factors…) and at the genetic level.